Form 4: Johnson & Johnson Reduces CVRx Stake

Johnson & Johnson, through its subsidiary, reported the sale of 2,700 shares of CVRx, Inc. common stock in two transactions.

Summary

• Johnson & Johnson, identified as a 10% owner and director of CVRx, Inc., reported transactions involving the sale of common stock.
• On November 21, 2025, Johnson & Johnson Innovation JJDC, Inc., a wholly-owned subsidiary of Johnson & Johnson, sold 500 shares of CVRx, Inc. Common Stock at a price of $10.00 per share.
• Following this transaction, Johnson & Johnson's indirect beneficial ownership stood at 4,049,398 shares.
• On November 24, 2025, an additional 2,200 shares of CVRx, Inc. Common Stock were sold by Johnson & Johnson Innovation JJDC, Inc. at a weighted average price of $10.06 per share, with prices ranging from $10.00 to $10.10.
• After the second transaction, Johnson & Johnson's indirect beneficial ownership in CVRx, Inc. decreased to 4,047,198 shares.
• The transactions were made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 4

Explanation: A significant 10% owner and director, Johnson & Johnson, reduced its stake in CVRx, Inc. by selling 2,700 shares, which can be perceived negatively by the market, although the amount is relatively small compared to total holdings.

Negatives

• A significant 10% owner and director, Johnson & Johnson, reduced its stake in CVRx, Inc. by selling 2,700 shares.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders may view the reduction in stake by a significant institutional investor and director as a negative signal regarding the company's near-term prospects or valuation.

Next Steps

• The Reporting Person undertakes to provide full information regarding the number of shares sold at each separate price within the reported range upon request to the Issuer, any shareholder, or the SEC staff.

Key Dates

Recommendation

Johnson & Johnson, a 10% owner and director, sold a relatively small portion of its CVRx, Inc. shares. While insider selling can be a negative signal, the volume is not substantial enough to warrant a 'sell' recommendation without further information on the company's fundamentals or J&J's strategic rationale. Investors should 'hold' and monitor future insider activity and company performance.

Keywords

CVRx Inc., CVRX, Johnson & Johnson, JJDC, Insider Sale, Form 4, Beneficial Ownership, Stock Sale, Medical Devices